These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30662360)

  • 1. Establishing a prediction model for prostate cancer bone metastasis.
    Chen S; Wang L; Qian K; Jiang W; Deng H; Zhou Q; Wang G; Liu X; Wu CL; Xiao Y; Wang X
    Int J Biol Sci; 2019; 15(1):208-220. PubMed ID: 30662360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients.
    Peng C; Juan C; Mao W; Jinghe Y; Renli T
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3832-3839. PubMed ID: 35731052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study.
    Chen S; Yang Y; Peng T; Yu X; Deng H; Guo Z
    Int J Med Sci; 2020; 17(10):1366-1374. PubMed ID: 32624693
    [No Abstract]   [Full Text] [Related]  

  • 4. Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume.
    Lu YF; Zhang Q; Chen HY; Chen JY; Pan Y; Xu CC; Xu JX; Yu RS
    Medicine (Baltimore); 2019 Jun; 98(26):e16289. PubMed ID: 31261602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer.
    Chaoying L; Chao M; Xiangrui Y; Yingjian H; Gang Z; Yunhan R; Yu G
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):391-398. PubMed ID: 35113414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 9. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of prostate health index in predicting bone metastasis of prostate cancer before bone scanning.
    Sun H; Zhu Y; Guo H; Jiang S; Guo H; Chen S
    Int Urol Nephrol; 2022 Dec; 54(12):3079-3086. PubMed ID: 35987936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
    Björk T; Lilja H; Christensson A
    BJU Int; 1999 Dec; 84(9):1021-7. PubMed ID: 10571627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
    Cheng Y; Luo LP; Hu S; Li LN; Wu C; Wu B; Wang DW
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):876-881. PubMed ID: 33113631
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer.
    Xu N; Ke ZB; Chen YH; Wu YP; Chen SH; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    Front Oncol; 2020; 10():1547. PubMed ID: 32923401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.